Telix Acquires ImaginAb’s Biologics Platform and Therapeutic Pipeline

Telix's recent acquisition from ImaginAb includes its next-generation therapeutic pipeline, a novel biologics technology platform, and a state-of-the-art research laboratory. This ‘value-chain initiative’ consists of still-ex exploratory product assets with rich DLL3, integrin αvβ6, and other rights, making Telix better positioned to engage with lucrative areas of medicine that remain underserved therapeutically. The novel small-engineered antibody formats provide specific cancer targeting with a fast tumor uptake and washout, suitable for imaging and treatment of tumors with various radioisotopes, especially the alpha emitters.

It also provides Telix with a modern study laboratory in California as well as an experienced staff involved in protein engineering and the development of radiopharmaceuticals. This acquisition is in line with Telix’s growth plan of strengthening its innovation strength and expansion in treatment indications. Mr. Richard Valeix, the CEO of Telix, stated that such assets will take the company to the next level of precision medicine, while Dr. Anna M. Wu, the co-founder of ImaginAb, noted the partnership to bring next-generation radiotherapeutics.